Internalization of novel non-viral vector TAT-streptavidin into human cells


Näytä suppeat kuvailutiedot Rinne, Johanna - Albarran, Brian - Jylhävä, Juulia - Ihalainen, Teemu O - Kankaanpää, Pasi - Hytönen, Vesa P - Stayton, Patrick S - Kulomaa, Markku S - Vihinen-Ranta, Maija - 2012-06-17T20:14:08Z 2012-06-15 07:11:31 - 2012-06-17T20:14:08Z 2007 -
dc.identifier.issn 1472-6750 -
dc.description BioMed Central Open access -
dc.description.abstract Background The cell-penetrating peptide derived from the Human immunodeficiency virus-1 transactivator protein Tat possesses the capacity to promote the effective uptake of various cargo molecules across the plasma membrane in vitro and in vivo. The objective of this study was to characterize the uptake and delivery mechanisms of a novel streptavidin fusion construct, TAT47–57-streptavidin (TAT-SA, 60 kD). SA represents a potentially useful TAT-fusion partner due to its ability to perform as a versatile intracellular delivery vector for a wide array of biotinylated molecules or cargoes. Results By confocal and immunoelectron microscopy the majority of internalized TAT-SA was shown to accumulate in perinuclear vesicles in both cancer and non-cancer cell lines. The uptake studies in living cells with various fluorescent endocytic markers and inhibiting agents suggested that TAT-SA is internalized into cells efficiently, using both clathrin-mediated endocytosis and lipid-raft-mediated macropinocytosis. When endosomal release of TAT-SA was enhanced through the incorporation of a biotinylated, pH-responsive polymer poly(propylacrylic acid) (PPAA), nuclear localization of TAT-SA and TAT-SA bound to biotin was markedly improved. Additionally, no significant cytotoxicity was detected in the TAT-SA constructs. Conclusion This study demonstrates that TAT-SA-PPAA is a potential non-viral vector to be utilized in protein therapeutics to deliver biotinylated molecules both into cytoplasm and nucleus of human cells. -
dc.language.iso en -
dc.title Internalization of novel non-viral vector TAT-streptavidin into human cells -
dc.type fi=Artikkeli aikakauslehdessä | en=Journal article| -
dc.identifier.urn urn:nbn:uta-3-622 -
dc.identifier.doi 10.1186/1472-6750-7-1 -
dc.type.version fi=Kustantajan versio | en=Publisher's version| -
dc.subject.okm fi=Lääketieteen bioteknologia | en=Medical biotechnology| -
dc.journal.title BMC Biotechnology -
dc.journal.volume 7 -
dc.journal.number 1 -
dc.journal.volumepagerange 1-14 -
dc.oldstats 60 -

Viite kuuluu kokoelmiin:

Näytä suppeat kuvailutiedot